HCC38_Human_Cancer_Cell_Line_Study__Single_Cell__-sc-2013-07-04T13:26:57Z-2618
HCC38_Human_Cancer_Cell_Line_Study__Single_Cell__
This study aims to compare data generated from single cells which has been amplified using different methods, including the recently published MALBAC protocol.  The samples in this study are an amplified product, generated from single HCC38 cells.   These samples are PCR product, of approximately 500-5,000 bp in length and at a concentration of approximately 2.5 ug/mL.   Initially, we would like to test library prep from 100ng of this sample for comparison with other amplification methods which have been used previously to  investigate genomic rearrangements and mutations in single cells from the HCC38 cell line.    This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/
The HCC38 breast cancer cell line has previously been used as a model to explore the rate at which mutations occur during the cell cycle. Here we are assessing the applicability of a new whole genome amplification, called MALBAC,  which offers improved genome coverage in single cell genomic sequencing.   In this study, MALBAC amplification will be applied to single cells, related by a single cell division. The MALBAC amplification method is, in part, a PCR based method  which generates a product of  ~300-3,000 bp with a yield of 300-3,000 ng per single cell, depending on the condition and reagents used.   In the first instance, this study aims to compare the data generated from these cells with data generated previously using alternative methods for Whole Genome Amplification including Multiple Displacement Amplification and PCR based methods (PicoPlex).